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Abstract
Aims/hypothesis HbA1c is an important risk factor for car-
diovascular disease (CVD), with 1% higher HbA1c levels
associated with a 10–20% increased risk of CVD. Little is
known about the association between change in HbA1c over
time and cardiovascular risk in non-diabetic populations.
This study examined the association between change in
HbA1c over time and cardiovascular risk in a non-diabetic
British population.
Methods We used data on HbA1c collected at baseline and
at a second health examination 3 years later among a pop-
ulation of 5,790 non-diabetic men and women who partic-
ipated in the European Prospective Investigation of Cancer
(EPIC)–Norfolk. The association between change in HbA1c
over 3 years and incident cardiovascular events over the
following 8 years was examined using multivariate Cox re-
gression. We also examined whether information on change in
HbA1c over time improved prediction of cardiovascular
events over a single measure of HbA1c by comparing the area
under the receiver operating characteristic curves (aROC) and
computing the net reclassification improvement.
Results The mean change (SD) in HbA1c over 3 years was
0.13% (0.52). During 44,596 person-years of follow-up, 529
cardiovascular events occurred (incidence 11.9 per
1,000 person-years). Each 0.5% rise in HbA1c over 3 years
was associated with a 9% increase in risk of a cardiovascular
event (HR 1.09; 95% CI 1.01, 1.18) after adjustment for
baseline HbA1c and other major cardiovascular risk factors.
However, change in HbA1c was not associated with cardio-
vascular risk after adjustment for HbA1c at follow-up.
Multivariate models with and without information on
change in HbA1c over time showed a similar aROC of
0.78. Adding change in HbA1c to the model with HbA1c at
follow-up did not improve risk classification.
Conclusions/interpretation Addition of information on
change in HbA1c over 3 years did not improve the prediction
of CVD over and above information on HbA1c and other
major cardiovascular risk factors from a single time point.
Keywords Cardiovascular disease . Discriminatory ability .
Glycated haemoglobin (HbA1c) . Net reclassification
improvement . Prediction . Risk factors . Temporal change
Abbreviations
aROC Area under the receiver operating
characteristic curve
CVD Cardiovascular disease
EPIC–Norfolk European Prospective Investigation
of Cancer–Norfolk
NRI Net reclassification improvement
Introduction
Glycaemia is an important risk factor for cardiovascular
disease (CVD), not only in those with diabetes but across
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the range of blood glucose values [1, 2]. Previous studies
have suggested that HbA1c has a continuous and graded
relationship with CVD, with 1% higher HbA1c levels asso-
ciated with a 20% and 26% increased risk of CHD and total
mortality, respectively [3, 4]. Systematic reviews of rando-
mised controlled trials of tight glycaemic control among
patients with diabetes provide further evidence of a causal
relationship between blood glucose and CVD [5, 6]. However,
there are no trials of glucose-lowering therapy in people with
non-diabetic hyperglycaemia that have reported a reduction in
cardiovascular events [7]. Consequently, there remains uncer-
tainty over the benefits of lowering blood glucose to prevent
CVD in non-diabetic populations [2].
Previous studies examining the relationship between gly-
caemia and CVD were based on between-individual differ-
ences in levels of glycaemia [3, 4, 8]. Studies have tracked
glycaemic control and CVD risk in individuals with diabe-
tes, but glucose-lowering treatment contributes to change in
glycaemia and other cardiovascular risk factors in these
individuals. Little is known about change in glycaemia over
time and its association with CVD in non-diabetic popula-
tions. If an association does exist, it is unclear whether
information on change in glycaemia over time will improve
prediction of cardiovascular events compared with a single
measure of glycaemia and other major cardiovascular risk
factors. In a large British prospective cohort, we examined:
(1) the association between change in HbA1c over 3 years
and risk of CVD; (2) whether information on change in
HbA1c over time might improve prediction of CVD com-
pared with information collected at a single time point.
Methods
Study design and population We used data from the Euro-
pean Prospective Investigation of Cancer (EPIC)–Norfolk, a
large population-based prospective study of men and wom-
en aged 40–79 years residing in the county of Norfolk, UK.
Details of the study have been described elsewhere [9].
Between 1993 and 1997, 25,639 men and women attended
a baseline health examination, which included a self-
administered health and lifestyle questionnaire, medical his-
tory taking, physical examination and blood testing. Partic-
ipants completed questionnaires about their personal and
family history of disease, medication and lifestyle factors
including smoking habits. They were asked whether a phy-
sician had ever told them that they had any of the conditions
in a list that included diabetes, heart attack and stroke.
Anthropometric and blood pressure measurements and
non-fasting blood samples were also taken at the health
assessment.
Information on HbA1c at baseline was available for
around half of all participants, as funding for the test only
became available in 1995. HbA1c was measured on fresh
EDTA blood samples using high-performance liquid chro-
matography (Diamat Automated Glycated Hemoglobin An-
alyzer; Bio-Rad Laboratories, Hemel Hemstead, UK),
which was standardised to the Diabetes Control and
Complications Trial (DCCT) assay.
The study was approved by the Norwich District Health
Authority Ethics Committee. All participants gave written
informed consent. EPIC–Norfolk is similar to a nationally
representative sample for anthropometric indices, blood
pressure and serum lipids, albeit with a lower prevalence
of cigarette smoking [9].
Participants were invited to attend a second health as-
sessment after 3 years (1998–2001), at which identical
measurements were taken, and 15,028 participants (59%)
attended. Results from the health examinations on risk factors
such as total cholesterol, blood pressure and HbA1c were
reported to the participants’ general practitioners so that they
could assume responsibility for follow-up, confirmation of the
diagnosis and organisation of care.
We limited our analysis to individuals with complete data
for HbA1c at the baseline and second health examinations
(n=6,372). Those with complete data on HbA1c were
healthier than those without with regard to risk factors at
baseline (electronic supplementary material [ESM] Table 1).
We further excluded individuals with clinically diagnosed
diabetes (self-reported physician-diagnosed diabetes, diabe-
tes medication or diet modification due to diabetes, diabetes
identified on hospital records, diabetes registers or diabetes
coded on death certificates) [10] at both health examinations
(n=245). We then excluded those with prior CVD at the
baseline examination and those who developed a first CVD
event up to the second health examination (n=337), leaving
5,790 individuals for our main analyses. We calculated the
change in HbA1c for each individual, the main exposure in
this study, by subtracting baseline HbA1c values from values
at the second health examination.
Follow-up and ascertainment of CVD We followed up par-
ticipants who were free of CVD at the time of their second
health examination for the development of a first CVD event
or death. We report results for follow-up from the second
health examination to 31 March 2008, a median of 8.1 years
(interquartile range 7.7–8.4). Incident CVD was defined as a
composite of fatal or non-fatal CVD, including hospitalisation
from CHD and stroke; or death from CHD, stroke or periph-
eral vascular disease. Vital status for all EPIC–Norfolk partic-
ipants was obtained via death certification at the Office for
National Statistics. Participants admitted to a hospital were
identified by their National Health Service number. Hospitals
were linked to the East Norfolk Health Authority database,
which identifies all hospital contacts throughout England and
Wales for Norfolk residents. Hospital record data and vital
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status information were complete for 95% and 99% of
participants, respectively. Previous validation studies in
this prospective cohort indicated high validity of such case
ascertainment [11].
Statistical analyses Baseline characteristics and change in
HbA1c over 3 years were summarised by CVD outcome,
using percentages, means (SD) and medians (interquartile
ranges). We tested for differences between groups using χ2
tests for categorical variables, and t tests or Kruskal–Wallis
tests for normally or non-normally distributed continuous
variables.
The distribution of HbA1c at baseline and the second
health examination and change in HbA1c was approximately
normal. We calculated the mean values of the three meas-
ures and tested whether the change in HbA1c over time was
different from zero.
We calculated cardiovascular event rates by levels of
baseline HbA1c (<5%, 5.0–5.4%, 5.5–5.9% and ≥6.0%
[<30, 31–36, 37–41 and ≥42 mmol/mol, respectively]) and
change in HbA1c over time (increased and unchanged or
decreased). We computed Kaplan–Meier curves for groups
characterised by different levels of baseline HbA1c, and for
individuals with high and low values of baseline HbA1c
(according to the median value in this population) and
changes in HbA1c over time (increased vs decreased or
unchanged). We also computed Kaplan–Meier curves using
different cut-off points to define high/low values of baseline
HbA1c (HbA1c values of 5.7%and 6.0% [39 and 42mmol/mol]
instead of the median value). The differences between groups
with different baseline HbA1c and changes in HbA1c were
tested using the logrank test.
To examine the independent association of HbA1c at base-
line and HbA1c at follow-up and change in HbA1c over 3 years
with CVD risk, we fitted five multivariate Cox proportional
hazards models which included different variables as follows:
(1) Model 1: HbA1c at baseline and change in HbA1c over
3 years; (2) Model 2: HbA1c at baseline, age, sex, smoking, a
family history of CVD, systolic blood pressure and serum
total cholesterol; (3) Model 3: HbA1c at baseline, change in
HbA1c over 3 years, age, sex, smoking, a family history of
CVD, systolic blood pressure and serum total cholesterol; (4)
Model 4: HbA1c at follow-up, age, sex, smoking, a family
history of CVD, systolic blood pressure and serum total
cholesterol; (5) Model 5: HbA1c at follow-up, change in
HbA1c over 3 years, age, sex, smoking, a family history of
CVD, systolic blood pressure and serum total cholesterol.
To determine whether information on change in HbA1c
over 3 years improved risk prediction of the model which
included HbA1c measured at baseline or follow-up, we
compared the area under the receiver operating characteristic
curve (aROC) for the models with and without information on
change in HbA1c, using a non-parametric method [12].
To account for concurrent changes in other risk factors,
we adjusted for changes in systolic blood pressure, total
cholesterol and BMI. According to the new diagnostic cri-
teria for diabetes, we performed sensitivity analyses to
check if the main results would be altered when excluding
those with an HbA1c ≥6.5% and ≥7.0% (≥48 and
≥53 mmol/mol).
For each model, we calculated the probability of CVD
events over 8 years for each individual using methods
previously described by D’Agostino et al [13], and then
stratified participants into four risk categories (<5.0%, 5.0–
9.9%, 10.0–19.9% and ≥20%). To demonstrate the benefits
of using information on change in HbA1c over time for
prediction of CVD in clinical practice, we calculated the
net reclassification improvement (NRI) to determine whether
information on change in HbA1c over time helped improve
risk classification by the models with HbA1c at baseline or
follow-up (Model 3 vs Model 2, and Model 5 vs Model 4)
[14].
Results
Baseline characteristics of study population The baseline
characteristics of the study population are summarised in
Table 1. The mean age of participants at baseline was 57.2
(SD 9.3) years, and 2,451 (42.3%) were male. Individuals
who developed CVD were, on average, 8 years older than
those who remained free of CVD. They were more likely to
be male, current smokers, to have a family history of CVD,
and be prescribed antihypertensive and lipid-lowering
drugs, compared with those who did not develop CVD.
Those who developed CVD also had higher baseline levels
of BMI, systolic blood pressure, total cholesterol, triacyl-
glycerol and HbA1c, and lower HDL-cholesterol values.
There was no difference in social class between the two
groups.
Change in HbA1c over time Mean HbA1c values (SD) at
baseline and the second health examination were 5.19%
(33 mmol/mol) (0.58%) and 5.32% (35 mmol/mol)
(0.47%), respectively. The mean difference between the
two measures of HbA1c was 0.13% (0.52%) (p<0.001).
Rates of cardiovascular events During 44,596 person-years
of follow-up, there were 529 first CVD events, a cardiovas-
cular event rate of 11.9 per 1,000 person-years. Figure 1
shows cardiovascular event rates in individuals with differ-
ent levels of baseline HbA1c by change in HbA1c from
baseline to the second health examination. Individuals
whose HbA1c values increased over time were more likely
to experience a cardiovascular event compared with those
whose HbA1c values decreased or were unchanged, except
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for those with a baseline HbA1c <5.0% (<30 mmol/mol).
Kaplan–Meier curves for individuals categorised by
different levels of baseline HbA1c (Fig. 2) showed that
levels of baseline HbA1c differed significantly with regard
Table 1 Baseline characteristics of EPIC–Norfolk participants by CVD outcome (n=5,790)






Age, mean (SD), years 57.2 (9.3) 56.5 (9.2) 64.5 (7.7) <0.001
Male sex, n (%) 2,451 (42.3) 2,138 (40.6) 313 (59.2) <0.001
Social class I–IIIab, n (%) 3,689 (64.6) 3,366 (64.8) 323 (62.6) 0.320
Smoking statusb, n (%)
Current smoker 534 (9.2) 477 (9.1) 57 (10.8) <0.001
Former smoker 2,298 (40.0) 2,040 (39.1) 258 (49.1)
Non-smokers 2,918 (50.8) 2,707 (51.8) 211 (40.1)
Family history of CVD, n (%) 3,019 (52.1) 2,699 (51.3) 320 (60.5) <0.001
BMI, mean (SD), kg/m2 25.9 (3.7) 25.8 (3.8) 26.6 (3.8) <0.001
Systolic blood pressure, mean (SD), mmHg 133.5 (17.5) 132.7 (17.2) 141.8 (18.8) <0.001
Total cholesterol, mean (SD), mmol/l 6.1 (1.1) 6.1 (1.1) 6.4 (1.2) <0.001
HDL-cholesterol, mean (SD), mmol/l 1.5 (0.4) 1.5 (0.4) 1.4 (0.4) <0.001
Triacylglycerol, median (interquartile range), mmol/l 1.4 (1.0–2.1) 1.4 (1.0–2.1) 1.7 (1.2–2.3) <0.001
HbA1c
DCCT units: mean (SD), % 5.2 (0.6) 5.2 (0.6) 5.4 (0.6) <0.001
IFCC units, mmol/mol 33 33 36
Change in HbA1c, mean (SD), % 0.13 (0.52) 0.13 (0.51) 0.09 (0.55) 0.114
Use of antihypertensive drugs, n (%) 727 (12.6) 586 (11.1) 141 (26.7) <0.001
Use of lipid-lowering drugs, n (%) 54 (0.9) 42 (0.8) 12 (2.3) <0.001
a p values represent the difference between individuals who developed CVD and those who did not develop CVD using t tests or Kruskal–Wallis
tests for normally or non-normally distributed continuous variables and χ2 tests for categorical variables
b Registrar General’s Social Class: class I, professional occupations; class II, managerial and technical occupations; class IIIa, skilled occupations
(non-manual); class IIIb, skilled occupations (manual); class IV, partly skilled occupations; class V, unskilled occupations; the numbers do not add
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HbA1c at baseline
Fig. 1 Rates of first cardiovascular events over 8 years in individuals
with different levels of baseline HbA1c by change in HbA1c between
baseline and the second health examination. White bar, decreased or
stable HbA1c over time; grey bar, increased HbA1c over time. A
significant difference in cardiovascular event rates was observed in
individuals with a baseline HbA1c 5.0–5.4% and 5.5–5.9% (p<0.05).
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Follow-up (years)
Fig. 2 Kaplan–Meier curves for development of cardiovascular events
in individuals with different levels of baseline HbA1c, with significant
difference across groups (p<0.001). Dotted line, HbA1c <5.0%; dashed
line, HbA1c 5.0–5.4%; dashed–dotted line, HbA1c 5.5–5.9%; solid line,
HbA1c ≥6.0%. To convert values for HbA1c in % into mmol/mol,
subtract 2.15 and multiply by 10.929
Diabetologia (2013) 56:1004–1011 1007
to development of a cardiovascular event over the follow-up
period (logrank test, p<0.001). Figure 3 shows Kaplan–
Meier curves for individuals with high and low values of
baseline HbA1c (according to the median value of 5.2%
[33 mmol/mol] in this population) and changes in HbA1c
over time (increased vs unchanged or decreased). Individu-
als with a high baseline HbA1c value and whose HbA1c
values increased over time were more likely to develop a
cardiovascular event than were those with a similar baseline
HbA1c but with unchanged or decreased HbA1c values over
time and those with a low baseline HbA1c value (p<0.001).
However, in those with a low baseline HbA1c, change in
HbA1c over time was not associated with the development
of a cardiovascular event (Fig. 3). Similar findings were
observed when HbA1c cut-off points of 5.7% and 6.0%
(39 and 42 mmol/mol) were used instead of the median
value.
Relative risk of cardiovascular events Table 2 shows the
risk of a first cardiovascular event (HR) for change in HbA1c
over 3 years and other major cardiovascular risk factors
including age, sex, smoking status, family history of CVD,
systolic blood pressure, total cholesterol and use of lipid-
lowering drugs. Change in HbA1c was significantly associ-
ated with cardiovascular risk. Each 0.5% increase in HbA1c
over 3 years was associated with a 9% higher risk of CVD
(HR 1.09; 95% CI 1.01, 1.18) after adjustment for baseline
HbA1c and other major cardiovascular risk factors (Model 3).
A 1% higher value of baseline HbA1c was associated with a
19% higher risk of CVD (HR 1.19; 95% CI 1.01, 1.39). These
HRs remained unchanged after adjustment for temporal
changes in levels of systolic blood pressure, total cholesterol
and BMI. When we further adjusted Model 3 for HDL-
cholesterol and use of antihypertensive drugs, the association
between change in HbA1c and CVD events was attenuated
(HR 1.06; 95% CI 0.97, 1.15). Models with and without
information on change in HbA1c over time showed similar
discriminatory ability (aROC 0.78 [95% CI 0.76, 0.80] for
both Models 2 and 3; p=0.70). When adjusting for HbA1c at
follow-up and other major risk factors, change in HbA1c over
time was not associated with risk of CVD in the following
8 years (Model 5). As shown in Table 2, adding information
on change in HbA1c over time did not improve predictive
ability over information on HbA1c at follow-up (aROC 0.78
[95% CI 0.76, 0.80] for both Models 4 and 5; p=0.99). We
found similar results for every SD change in HbA1c (ESM
Table 2). The main results were not altered when excluding
individuals with HbA1c ≥6.5% and ≥7.0% (≥48 and
≥53 mmol/mol). The inclusion of information on change in
HbA1c over time did not improve risk classification of the
models with HbA1c at baseline or follow-up (Model 3 vs
Model 2: NRI 0.30%, p=0.71; Model 5 vs Model 4: NRI
0%, p=0.50).
Discussion
We have shown that individuals whose HbA1c values in-
creased over a period of 3 years had higher rates of cardio-
vascular events compared with those whose HbA1c values
were unchanged or reduced over time. In multivariate re-
gression models, change in HbA1c over time was associated
with the risk of developing a CVD event independently of
baseline HbA1c and other major cardiovascular risk factors.
However, the association was not significant after adjust-
ment for HbA1c at follow-up. Adding information on
change in HbA1c over time to a model that included baseline
HbA1c (or most recent HbA1c) and other major risk factors
did not improve the prediction of CVD events with regard to
discriminatory ability and risk classification.
Comparison with previous studies Although previous stud-
ies reported that HbA1c is an important risk factor for CVD,
little evidence exists regarding the association between
change in measures of glycaemia over time and cardiovas-
cular risk in general populations. Although some previous
studies found no association between HbA1c and CVD risk
[15, 16], data from a recent meta-analysis suggest that 1%
higher HbA1c levels are associated with a 10–20% increased
risk of CVD [3, 4], which is consistent with our results. Our
finding that change in HbA1c values over time is indepen-
dently associated with risk of CVD events, particularly in
non-diabetic individuals with moderate-to-high baseline
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Follow-up (years)
Fig. 3 Kaplan–Meier curves for development of cardiovascular events
in individuals with high and low values of baseline HbA1c (according
to the median value of 5.2% or 33 mmol/mol in this population) and
change in HbA1c over time (increased, +ve; decreased or unchanged,
−ve), with significant difference across groups (p<0.001). Dotted line,
low baseline HbA1c and −ve change; dashed line, low baseline HbA1c
and +ve change; dashed–dotted line, high baseline HbA1c and −ve
change; solid line, high baseline HbA1c and +ve change
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Trial evidence to date suggests that cardiovascular risk
may be reduced through tight glycaemic control in individ-
uals with diabetes [5, 6]. However, there is still uncertainty
about the effects of glucose-lowering approaches on cardio-
vascular risk in individuals with a lesser degree of dysgly-
caemia. The Nateglinide and Valsartan in Impaired Glucose
Tolerance Outcomes Research (NAVIGATOR) trial, which
aimed to reduce CVD risk by means of a glucose-lowering
drug among individuals with impaired glucose tolerance,
was not able to show the beneficial effect as the trial did
not meet its glycaemic control target [7]. In fact, while a
small reduction in fasting plasma glucose levels was observed,
2 h postchallenge glucose was elevated in the intervention
group compared with the control group. Similarly, the recently
reported Outcome Reduction with Initial Glargine Interven-
tion (ORIGIN) trial found no difference in cardiovascular
outcomes over 6 years between those receiving basal insulin
to target normal fasting plasma glucose level and those
receiving standard care [17].
Implications There is evidence to suggest that measuring gly-
caemia might contribute to the estimation of CVD risk in
addition to other major cardiovascular risk factors. One example
is the UK Prospective Diabetes Study (UKPDS) risk engine,
which incorporates HbA1c and other risk factors to estimate
cardiovascular risk in people with diabetes [18]. The only car-
diovascular risk score developed in the general population that
includes measures of glycaemia (fasting plasma glucose and 2 h
plasma glucose) is the Diabetes Epidemiology: Collaborative
Analysis of Diagnostic Criteria in Europe (DECODE) risk
score [19]. We have previously shown that the addition of
HbA1c to the standard Framingham risk equation modestly
improved its predictive ability in British men, but did not
improve risk classification [20]. The present analysis suggests
that, although information on change in HbA1c over 3 years
was associated with cardiovascular risk independently of
baseline HbA1c and other major risk factors, the potential
contribution to risk prediction models appears limited.
Our results support the idea that approaches to lowering
blood glucose might have the potential to prevent CVD
among people with non-diabetic hyperglycaemia, although
this needs to be confirmed by results from ongoing trials such
as the Acarbose Cardiovascular Evaluation (ACE) trial (http://
clinicaltrials.gov/ct2/show/NCT00829660, accessed 24 Jan
2013). Alongside this high-risk approach, our results also
provide support for population-based prevention strategies
[21]. A rise in the mean value of HbA1c over 3 years observed
in this study points to a shift in the distribution of glycaemia in
the non-diabetic population over a relatively short time. Inter-
ventions to shift the distribution of glycaemia, and other risk
factors, in the opposite direction, or to reduce themagnitude of
the observed shift, are likely to be associated with a reduction
in the population burden of CVD.
Strengths and limitations To our knowledge, this study is
the first to examine the association between change in
Table 2 Relative risk (HR) estimated from multivariate Cox regression for the association between risk factors and development of a first
cardiovascular event over 8 years
Risk factor HR (95% CI)
Model 1a Model 2a Model 3a Model 4a Model 5a
Change in HbA1c over 3 years
(every 0.5% change)
1.13 (1.06, 1.21)* – 1.09 (1.01, 1.18)* – 1.00 (0.92, 1.09)
Baseline HbA1c (every 1.0% higher) 1.71 (1.51, 1.95)
* 1.08 (0.94, 1.24) 1.19 (1.01, 1.39)* – –
HbA1c at second health examination
(every 1.0% higher)
– – – 1.19 (1.04, 1.36)* 1.19 (1.01, 1.39)*
Female sex – 0.48 (0.40, 0.58)* 0.48 (0.40, 0.58)* 0.48 (0.40, 0.58)* 0.48 (0.40, 0.58)*
Age (every 1 year older) – 1.09 (1.08, 1.10)* 1.09 (1.08, 1.10)* 1.09 (1.08, 1.10)* 1.09 (1.08, 1.10)*
Current smokers – 1.55 (1.17, 2.06)* 1.55 (1.17, 2.06)* 1.55 (1.17, 2.06)* 1.55 (1.17, 2.06)*
Total cholesterol (every 1 mmol/
l higher)
– 1.11 (1.03, 1.20)* 1.11 (1.03, 1.20)* 1.11 (1.03, 1.20)* 1.11 (1.03, 1.20)*
Systolic blood pressure
(every 1 mmHg higher)
– 1.01 (1.00, 1.01)* 1.01 (1.00, 1.01)* 1.01 (1.00, 1.01)* 1.01 (1.00, 1.01)*
Family history of CVD – 1.20 (1.01, 1.44)* 1.20 (1.01, 1.44)* 1.20 (1.01, 1.44)* 1.20 (1.01, 1.44)*
Use of lipid-lowering drugs – 2.25 (1.62, 3.12)* 2.25 (1.62, 3.12)* 2.25 (1.62, 3.12)* 2.25 (1.62, 3.12)*
aROC (95% CI)b 0.60 (0.58, 0.63) 0.78 (0.76, 0.80) 0.78 (0.76, 0.80) 0.78 (0.76, 0.80) 0.78 (0.76, 0.80)
a HRs for variables in each model were adjusted for all other covariates whose HR values were presented in the table and the results were not
changed after adjustment for BMI at baseline, changes in systolic blood pressure, total cholesterol, HDL-cholesterol and BMI over time
b p values for comparing aROC: p<0.001 Model 1 vs Model 3; p=0.702 Model 2 vs Model 3; p=0.987 Model 4 vs Model 5
*p<0.05
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HbA1c and future risk of CVD. We used data from a large
population-based prospective study with robust ascertain-
ment of cardiovascular outcomes over a long follow-up.
However, to address our research question, we included
only participants with complete data on HbA1c at baseline
and the second health examination, who were generally
healthier than those excluded, according to their baseline
risk factor profiles (ESM Table 1). As HbA1c testing became
available in 1995, most participants enrolled between 1993
and 1994 were excluded (missing by design). These partic-
ipants were less healthy than those included in our main
analysis. This is likely to have led to underestimation of the
true cardiovascular risk in the whole cohort and might
therefore have influenced estimates of the association be-
tween change in HbA1c and CVD risk.
As the baseline and second health examinations in EPIC–
Norfolk took place in the 1990s and early 2000s, before the
introduction of new HbA1c diagnostic criteria [22], in our
main analysis we did not exclude those with an HbA1c
≥6.5% (≥48 mmol/mol) at either health examination, as we
assumed that they were not prescribed any glucose-lowering
treatment. Furthermore, as results for HbA1c were sent to
participants’ general practitioners, those with an HbA1c
≥7.0% (≥53 mmol/mol) at the time were assumed to have
been followed up and a diagnosis of diabetes confirmed and
recorded in diabetes registers and clinical records. These
participants would therefore be captured by our methods
of diabetes ascertainment using multiple sources of infor-
mation. In fact, a previous capture–recapture analysis in this
cohort showed that this method of ascertainment identified
99% of all clinically incident cases of diabetes, when com-
pared with diagnostic information from a comprehensive
review of clinical records [23]. Moreover, in our sensitivity
analyses the exclusion of individuals with an HbA1c ≥6.5% or
≥7.0% (≥48 or ≥53 mmol/mol) did not alter the main results.
It is possible that regression to the mean in HbA1c may
have altered the result of the association between change in
HbA1c and CVD risk. For example, individuals with a larger
increase in HbA1c over time tended to be those with a lower
baseline HbA1c, who were actually at lower risk of CVD.
This might have led to an underestimation of the association
between change in HbA1c and CVD risk. As HbA1c increases
with age, we have taken into account the possible effect of
increasing age on the association between change in HbA1c
over time and CVD risk by adjusting the association for age
and other risk factors. HbA1c values are influenced by some
disorders affecting the lifespan of erythrocytes, such as hae-
moglobinopathy [22]. However, these conditions are rare in
this white population. Last, as 99% of EPIC–Norfolk partic-
ipants were white, the generalisability of our findings to other
ethnic groups and populations might be limited.
We conclude that the inclusion of information on change
in HbA1c over time did not improve prediction of CVD over
and above information on HbA1c and other major cardio-
vascular risk factors at a single time point in this non-
diabetic British population.
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